GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
01 déc. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be...
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
28 nov. 2023 16h05 HE
|
GeneDx Holdings Corp.
GeneDx company management will participate in the 6th Annual Evercore ISI HealthCONx Conference.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 nov. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17,...
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
30 oct. 2023 16h05 HE
|
GeneDx Holdings Corp.
Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue Expanded gross margins to 48% in continuing operations and delivered 52% year-over-year...
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
09 oct. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 sept. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 22, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1,...
GeneDx Announces Evolution of Executive Leadership Team
11 sept. 2023 08h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and...
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
06 sept. 2023 08h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its...
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
21 août 2023 07h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the...
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 août 2023 20h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of August 8,...